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Evaluating antipsychotic prescribing in the intensive care
unit and across the continuum of care
Michael Pasqualicchio, Pharm.D., Heidi Clarke, Pharm.D., BCCCP
Baptist Hospital of Miami, Department of Pharmacy; Miami, FL

Background
 Delirium is common in the critically ill with a prevalence of up to 80% in
mechanically ventilated patients in the Intensive Care Unit (ICU)1,2
 ICU related delirium is a clinical diagnosis made based on screening
tools such as the Confusion Assessment Method for the ICU (CAM-ICU)3
 Risk factors for delirium occurrence include benzodiazepine use, age,
dementia, emergency surgery or trauma, and increasing severity of
illness3
 The 2018 PADIS Guidelines published by the Society of Critical Care
Medicine recommend against the routine use of both typical and
atypical antipsychotic agents for either the prevention or treatment of
delirium. Non-pharmacological strategies are preferred3
 Evidence suggests that the use of antipsychotics in patients with
delirium is not associated with a shorter duration of delirium,
mechanical ventilation or ICU length of stay. Antipsychotic use is also
not associated with decreased mortality3
 Antipsychotics, when ordered in the ICU, are commonly inappropriately
continued post transfer from the ICU and following discharge from the
hospital3,4,5,6
 Many undesirable side effects accompany long-term use of
antipsychotics such as weight gain, hyperlipidemia, QTc prolongation,
extrapyramidal symptoms (EPS), and increased mortality in elderly
patients with dementia related psychosis7

Objectives





Determine the incidence of antipsychotic initiation in the ICU for
delirium prevention or treatment at Baptist Hospital of Miami
including the agent, dose, frequency, and duration of therapy
Determine the rate of continuation of newly initiated antipsychotics
following discharge from both the ICU and hospital
Evaluate the use and documentation of CAM-ICU scores as a tool for
initiating and discontinuing antipsychotic therapy appropriately
Establish the foundation for the development of a pharmacist-driven
protocol to aid in the discontinuation of antipsychotic agents when
used for ICU-related delirium8

Methods
 Study design: Single-center, retrospective chart review of anti-psychotic
naïve patients admitted to the ICU at Baptist Hospital of Miami and
initiated on an antipsychotic between June 1, 2018 and July 1, 2019
 Inclusion criteria: Individuals ≥ 18 years old, patients initiated on a newstart antipsychotic in the ICU receiving at least 2 days of therapy
 Exclusion criteria: Patients ordered “as needed” or one-time
antipsychotics, patients on antipsychotic prior to hospitalization or ICU
admission, patients who did not survive to discharge, pregnant patients
 Primary outcome: Percentage of patients prescribed a new-start
antipsychotic in the ICU that was continued post-hospital discharge
based on the discharge medication reconciliation and discharge
summary
 Secondary outcomes: Percentage of patients prescribed a new-start,
standing antipsychotic in the ICU that was continued post-ICU discharge
 Antipsychotic agent, regimen, and duration
 CAM-ICU administration, documentation, and result

ConfusionRESULTS
Assessment Method for the ICU (CAM-ICU)
1. Acute onset or fluctuating course compared to baseline or within the last 24 hours
2. Inattention (letters attention test)
3. Altered level of consciousness (Richmond Agitation-Sedation Scale)
4. Disorganized thinking
Delirium diagnosis if 1 and 2 are present with either 3 or 4. CAM-ICU should be reassessed at another time if RASS <-3

Results
Baseline Characteristics N=76
Mean age, years

67

Gender - male, n (%)

56 (74)

Antipsychotic, n (%):
Quetiapine
Risperidone
Olanzapine

67 (88)
5 (7)
4 (5)

Antipsychotic Prescribing Trends

Discharge location of n=37
patients continued on
antipsychotic

14 (18%)

CAM-ICU

N=76

Patients with at least one
documented positive CAM-ICU
score, n (%)
Number of patients with no
documented CAM-ICU score,
n (%)
Number of patients “unable to
assess”, n (%)
Number of patients with at least
one negative documented CAMICU score, n (%)
Reason for unable to assess
“Non-English speaking”
“RASS -4/-5”
“Extremely hard of hearing”
“Refused”
“Severe mental disability”
“Blind”

0 (0)

Quetiapine Regimen
Initial daily dose, n (%):
12.5 mg
25 mg
50 mg
100 mg
Maximum daily dose, n (%):
12.5 mg
25 mg
37.5 mg
50 mg
75 mg
100 mg
125 mg
150 mg
200 mg
450 mg

13 (17)

37 (49%)
25 (33%)

7 (9)
56 (74)

Skilled nursing facility

13

Home

8

Acute inpatient rehab

5

Home with services

4

Long term acute care

2

Rehab

2

Subacute rehab

1

Psychiatric unit

1

Transfer

1

Discontinued in the ICU
Discontinued in step-down unit
Continued post hospital discharge
n=67
7 (10)
26 (39)
28 (42)
6 (9%)

5 (8)
16 (24)
1 (2)
25 (37)
1 (2)
14 (21)
1 (2)
2 (3)
1 (2)
1 (2)

Timing of Therapy and Length of Stay
Overall
population
N=76

Discontinued Discontinued
in ICU
in step down
n=14
n=25

Mean ICU day of antipsychotic initiation
Mean ICU LOS (days)

ICU day 8.2

ICU day 10.0

12.9

17.8

11.7

11.9

Mean duration of
antipsychotic therapy
(days)
Mean duration of
sedation/opioid
(days)
Mean duration of
intubation (days)

12.0 (1-51)

5.5

10.8

15.2

6.0

7.0

6.0

6.0

7.0

9.9

6.0

6.4

ICU day 8.0

Continued post
hospital discharge
n=37
ICU day 7.5

Conclusions
 Antipsychotic-naïve patients who are initiated on an antipsychotic in
the ICU are continued on the agent at a rate of 49% at hospital
discharge
 Antipsychotics initiated in the ICU are continued in the step-down
units at a rate of 82%
 Quetiapine is the most commonly prescribed antipsychotic agent in
the ICU
 Patients prescribed antipsychotic agents in the ICU are commonly on
prolonged courses of sedation. On average, antipsychotics are
started on day 8 of ICU admission
 Longer ICU length of stay was associated with a higher likelihood of
antipsychotic discontinuation prior to discharge
 Patients were most commonly initiated on quetiapine at a total daily
dose of 25 mg or 50 mg and titrated up to 50 mg or 100 mg
respectively
 Antipsychotic initiation and discontinuation was not associated with
CAM-ICU scores
 CAM-ICU scores were documented in 83% of patients however all
results were either “negative” or “unable to assess”
 Justification for inability to assess CAM-ICU scores included barriers
to communication and high levels of sedation

Limitations
 Small sample size
 Lack of documentation of antipsychotic indication
 Inconsistent documentation or administration of CAM-ICU

Future Implications
 Opportunity for education regarding the appropriate documentation
and utility of CAM-ICU scores
 Potential implementation of a pharmacist-driven protocol to ensure
patients are not discharged inappropriately on antipsychotic therapy
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